AVALO THERAPEUTICS, INC. Accrued Income Taxes, Current
AVALO THERAPEUTICS, INC. (AVTX) had Accrued Income Taxes, Current of $0 as of 2021-12-31, per its 10-K filed 2022-03-02.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current › Taxes Payable, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2022-03-02
- 2021-12-31: Accrued Income Taxes, Current $0.00.
- 2020-12-31: Accrued Income Taxes, Current $0.00.
- 2020-09-30: Accrued Income Taxes, Current $0.00.
- 2020-06-30: Accrued Income Taxes, Current $0.00.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-02 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
| 2019-12-31 | $551.67K 10-K · filed 2021-03-08 |
| 2019-09-30 | $1.01M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.39M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.81M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $2.03M 10-K · filed 2020-03-11 |
| 2018-09-30 | $2.20M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $2.17M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $2.27M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $2.26M 10-K · filed 2019-03-18 |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |